Bluebird bio (BLUE), Carlyle (CG), SK Capital Partners and Beacon Parent said late Monday that all required regulatory approvals have been received for the Bluebird bio's acquisition by Carlyle and SK Capital.
The companies said no additional approvals are needed, and the merger is expected to close soon on May 12.
Under the deal, Bluebird bio's shareholders will receive $3 per share in cash upfront and a contingent value right worth up to $6.84 per share, based on future sales milestones, bringing the total potential value to $9.84 per share.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。